M. Kraus & Co Sells 373 Shares of Becton, Dickinson and Company (NYSE:BDX)

M. Kraus & Co lowered its position in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 1.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,349 shares of the medical instruments supplier’s stock after selling 373 shares during the period. Becton, Dickinson and Company comprises about 1.9% of M. Kraus & Co’s portfolio, making the stock its 24th biggest position. M. Kraus & Co’s holdings in Becton, Dickinson and Company were worth $6,273,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. grew its position in Becton, Dickinson and Company by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 26,123,450 shares of the medical instruments supplier’s stock worth $6,369,681,000 after acquiring an additional 195,931 shares during the last quarter. Morgan Stanley grew its position in shares of Becton, Dickinson and Company by 4.5% in the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after buying an additional 435,168 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Becton, Dickinson and Company by 9.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,630,351 shares of the medical instruments supplier’s stock valued at $938,593,000 after buying an additional 304,629 shares during the last quarter. Clearbridge Investments LLC grew its position in shares of Becton, Dickinson and Company by 0.6% in the 4th quarter. Clearbridge Investments LLC now owns 3,154,438 shares of the medical instruments supplier’s stock valued at $769,147,000 after buying an additional 19,200 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at about $761,798,000. Institutional investors own 86.97% of the company’s stock.

Insider Activity

In other news, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the transaction, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at $472,876.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the sale, the senior vice president now owns 1,976 shares in the company, valued at $472,876.56. The disclosure for this sale can be found here. Insiders sold a total of 8,615 shares of company stock valued at $2,033,381 over the last three months. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.1 %

BDX stock traded down $0.17 during trading on Friday, reaching $238.23. 2,014,700 shares of the stock were exchanged, compared to its average volume of 1,451,796. The firm’s 50 day moving average is $234.35 and its 200 day moving average is $237.84. Becton, Dickinson and Company has a twelve month low of $224.00 and a twelve month high of $287.32. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm has a market cap of $68.85 billion, a P/E ratio of 52.47, a price-to-earnings-growth ratio of 2.05 and a beta of 0.44.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. The firm had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.86 earnings per share. As a group, research analysts forecast that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 83.70%.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of analyst reports. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target on the stock. Barclays upped their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Finally, StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $280.17.

Get Our Latest Stock Report on Becton, Dickinson and Company

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.